hypertension and prenatal care
Conditions
Interventions
Will be used omega 500 mg / day (DHA gestation 500 mg / day) - 400 mg DHA and 100 mg EPA - in the ratio of 4: 1. The dosages of heparin (40 mg / day enoxaparin) and ASA 100 mg / day as follows:
Group
Group 1B - users of heparin + omega
Group 2: Patients with acquired thrombophilia - Group 2A - users of heparin + ASA
heparin + ASA + omega users group
Group 3: Patients with risk factor for preeclampsia - Group 3A - users of ASA
group 3B - users of AAS + omega
Dietary supplement
Sponsors
Faculdade de Medicina de Barbacena
Faculdade de Medicina de Barbacena
Eligibility
Sex/Gender
Female
Age
19 Years to 45 Years
Inclusion criteria
Inclusion criteria: Pregnant women enrolled in prenatal care of the institution. Pregnant women who signed the free and informed consent form. Pregnant women who attend the appointments (with even a missed prenatal) and agree to perform the protocol of the service, clinical examinations and imaging. Pregnant women with hereditary or acquired thrombophilias identified previously. Pregnant women with identified risk factor for preeclampsia or CIUR selected from ACOG and NICE data adapted for this study: i. Identification of two anamnesis clinical data (clinical history of PE in previous pregnancy, history PE in first-degree relative, BMI> 35 kg / m2, hypertension, nephropathy, disease autoimmune). ii. Identification of anamnesis clinical data associated with changes in uterine artery doppler in the first trimester (IR, PI or bilateral doppler notch). iii. MAP identification> 100 in the first trimester of pregnancy associated with clinical history or Doppler altered uterine artery (PI, IR, uterine artery notch).
Exclusion criteria
Exclusion criteria: Pregnant women - under 19 years. Pregnant women who are absent from consultations - two or more consecutive prenatal absences. Pregnant women who do not accept to use the omega in the prenatal or have intolerance to the use of the omega. Smoking patients. Gestantes without risk factor or thrombophilia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of placental vascular resistance in association with omega - measured through the resistance index (RI) of the uterine artery through Doppler ultrasonography;Reduction of placental vascular resistance in association with omega - measured through the pulsatiity index (PI) of the uterine artery through Doppler ultrasonography | — |
Secondary
| Measure | Time frame |
|---|---|
| Preeclampsia Measured through the measurement of pregnant women 's blood pressure. Two evaluations at 4-hour intervals, with values ??equal to or greater than 140/90 mmHg + proteinuria at urinalysis of at least 300 mg / dl in 24-hour urine;Oligohydramnio Evaluation of the volume of amniotic fluid identified through sonographic examination through the amniotic fluid index (ILA) described by Phelan et al.;Restricted intrauterine growth (RCIU) Evaluation of fetal growth parameters identified by ultrasound examination. CIUR is considered when the fetus presents fetal growth below the 10th percentile for gestational age. Parameters: biparietal diameter, femur length and fetal abdominal circumference. | — |
Countries
Brazil
Contacts
Public ContactJuliana Zimmermmann
Faculdade de Medicina de Barbacena
Outcome results
None listed